In the BioHarmony Drug Report Database

"Preview" Icon

Epoetin beta

Procrit, NeoRecormon (epoetin beta) is a protein pharmaceutical. Epoetin beta was first approved as Procrit on 1997-07-16. It has been approved in Europe to treat anemia, autologous blood transfusion, chronic kidney failure, and neoplasms.

 

Trade Name

 

NeoRecormon
 

Common Name

 

epoetin beta
 

ChEMBL ID

 

CHEMBL2109092
 

Indication

 

anemia, autologous blood transfusion, chronic kidney failure, neoplasms
 

Drug Class

 

Erythropoietins

Image (chem structure or protein)

Epoetin beta structure rendering